This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There are several factors which increase the risk of cardiovasculardisease in survivors of spinal cord injury. They have a greater prevalence of obesity, dyslipidemia, metabolic syndrome and diabetes mellitus. Cardiovasculardisease in spinal cord injury: an overview of prevalence, risk, evaluation, and management.
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram. Original article: Mensah GA et al.
CLEAR trial was a double blind, randomized, placebo controlled trial of patients who were unable or unwilling to take statins due to unacceptable adverse effects and had or were at high risk for cardiovasculardisease. There was no increase in new onset diabetes mellitus or worsening of diabetes mellitus. There was 29.2
Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovasculardisease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Presented at: ACC 2024.
A study published in Nature Medicine evaluated the burden of type 2 diabetes and cardiovasculardisease attributable to sugar sweetened beverages in 184 countries [1]. million cases of new type 2 diabetes was attributable to sugar sweetened beverages worldwide, which was 9.8% In 2020, 2.2 of incident cases. In 2020, 2.2
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content